Randall Moreadith, MD, PhD
About Randall Moreadith, MD, PhD
Randall Moreadith, MD, PhD, serves as the Chief Development Officer at Serina Therapeutics, Inc., where he has been since 2024. He has extensive experience in polymer therapeutics and has held leadership positions in the biotechnology sector, including a previous role as President and CEO at the same company.
Current Role at Serina Therapeutics
Randall Moreadith serves as the Chief Development Officer at Serina Therapeutics, Inc., a position he has held since 2024. In this role, he is responsible for overseeing the development of therapeutic products and strategies aimed at addressing complex medical challenges. His current work is based in Huntsville, Alabama, where he continues to contribute to the company's mission of advancing innovative therapies.
Previous Leadership at Serina Therapeutics
Prior to his current role, Randall Moreadith was the President and CEO of Serina Therapeutics, Inc. from 2010 to 2024. During his tenure, he played a significant role in shaping the company's direction and growth. His leadership contributed to the successful merger of Serina Therapeutics into AgeX, which is now publicly traded on the NYSE under the symbol 'SER'.
Experience at Nektar Therapeutics
Randall Moreadith previously held the position of Chief Development Officer at Nektar Therapeutics for one year, from 2008 to 2009. In this role, he was involved in the development of therapeutic solutions, leveraging his expertise in polymer therapeutics and drug delivery systems.
Educational Background and Expertise
Randall Moreadith has an extensive educational background in the medical and scientific fields. He earned his MD from Duke University School of Medicine, specializing in Internal Medicine and Cardiology. He also obtained a PhD in Cellular and Molecular Biology from The Johns Hopkins University School of Medicine. Additionally, he studied Molecular Genetics at Harvard University, where he was recognized as a Howard Hughes Fellow. His expertise includes the development of polymer therapeutics, particularly using poly(oxazoline) technology for controlled release kinetics.
Partnerships and Technology Advancement
In his professional capacity, Randall Moreadith has been actively involved in advancing proprietary technology through collaborations with innovative companies. His focus is on developing life-changing drugs for challenging diseases, reflecting his commitment to improving patient outcomes through scientific innovation.